Which of the following is an FDA-approved labeled indication for levofloxacin? Select all that apply.

A. Upper respiratory tract infections are frequently viral in origin, rendering this sulfonamide combination ineffective. While it covers some respiratory pathogens, it is not a primary labeled indication for general upper respiratory infections. Clinical use is typically reserved for specific bacterial complications.

B. Constipation associated with opioid use results from activation of mu-opioid receptors in the gastrointestinal tract. This antimicrobial agent lacks any pharmacological activity on enteric motility or opioid receptors. It is exclusively an anti-infective and has no role in managing bowel dysfunction.

C. Urinary tract infections are a primary labeled indication for this synergistic combination. Sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. This sequential blockade of folic acid synthesis provides potent bactericidal activity against common uropathogens like Escherichia coli.

D. Headache symptoms from a common cold are typically managed with analgesics such as acetaminophen or nonsteroidal anti-inflammatory drugs. Sulfamethoxazole with trimethoprim does not possess analgesic or antipyretic properties. It is not indicated for the symptomatic relief of viral upper respiratory syndromes.

A. Rizatriptan is the active pharmaceutical ingredient for the brand Maxalt. While it belongs to the same selective 5-hydroxytryptamine 1B and 1D receptor agonist class, it is not the chemical constituent of Imitrex. It possesses a different pharmacokinetic profile.

B. Almotriptan is the generic name for the brand Axert. This compound is indicated for the acute treatment of migraine with or without aura in adults. It is a separate molecular entity from the drug requested in the question stem.

C. Sumatriptan is the generic name for Imitrex, the first triptan developed for clinical use. It acts as a selective agonist at vascular 5-HT1B and 5-HT1D receptors. This binding induces cranial vessel vasoconstriction and inhibits the release of proinflammatory neuropeptides.

D. Eletriptan is marketed under the brand name Relpax. It is a second-generation triptan used for migraine abortive therapy. It is not the active ingredient in Imitrex. Its metabolism and bioavailability differ significantly from those of sumatriptan.